{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-26-000092","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2026-11-16T11:08:15+00:00","discovered_at":"2026-11-16T11:15:10.277186+00:00","generated_at":"2026-11-16T11:15:47.518230+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.92,"calibrated_materiality_score":0.92,"confidence":"high","headline":"FDA issues Complete Response Letter for Summit's ivonescimab BLA in EGFR-mutant NSCLC","bullets":["FDA said substantial evidence of effectiveness is not established without a statistically significant overall survival benefit; PFS benefit alone failed to support a positive benefit-risk profile.","HARMONi met its PFS primary endpoint, but the primary OS analysis showed only a positive trend that was not statistically significant.","Post-hoc longer follow-up showed OS hazard ratio of 0.76 across the full, Asian and western patient populations.","Safety: 16 patients (7.3%) discontinued ivonescimab for TRAEs vs 11 (5.0%) on placebo; treatment-related deaths 4 (1.8%) vs 5 (2.3%).","Ivonescimab remains unapproved in the U.S. and Europe (China approval May 2024); Summit cites five positive Phase III studies and ongoing HARMONi-3, -7, -GI3, -GU1 trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-26-000092","json":"https://secwatch.observer/filing/0001599298-26-000092.json","markdown":"https://secwatch.observer/filing/0001599298-26-000092.md","text":"https://secwatch.observer/filing/0001599298-26-000092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000092/0001599298-26-000092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000092/smmt-20261115.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-16T11:15:47.518230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}